ACXP
Acurx Pharmaceuticals, Inc.
Key Financials
Net Income
$-7966538
↑ 43.5%
Operating Income
$-8091983
↑ 42.7%
EPS (Diluted)
$-5.32
↓ 511.5%
Cash & Equivalents
$14.5M
N/A
Total Liabilities
$2.4M
↓ 25.3%
Total Assets
$7.7M
↑ 99.3%
Shareholders' Equity
$5.3M
↑ 756.5%
Operating Cash Flow
$-6787782.00
↑ 34.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 424B3 | 5/12/2026 | View on SEC |
| 424B3 | 5/12/2026 | View on SEC |
| EFFECT | 5/11/2026 | View on SEC |
| EFFECT | 5/11/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| CORRESP | 5/7/2026 | View on SEC |
| CORRESP | 5/7/2026 | View on SEC |
| UPLOAD | 5/7/2026 | View on SEC |
| UPLOAD | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACXP |
| Company Name | Acurx Pharmaceuticals, Inc. |
| CIK | 1736243 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 917-533-1469 |